Clinical Research Focus. 25th Edition
J.P. Morgan’s Healthcare Conference: A Glimpse into the Optimistic Pulse of 2024
The biopharmaceutical industry, emerged from 2023’s continued downturn in finance deals and mergers and acquisitions (M&A) and showcased resilience and determination at the 2024 J.P. Morgan Conference. Notable M&A deals were heralded, signifying if not a recovery, at least a beacon of hope for the industry.
Please follow the link to learn more.
Türkiye’s Emerging Role in Clinical Research: Regulatory Updates and Simplified Processes
With a population exceeding 85 million and a robust, comprehensive healthcare infrastructure, Türkiye has quietly established itself as an undiscovered treasure in the field of clinical research. With a relatively low per capita number of clinical trials and a substantial pool of treatment-naive patients, Türkiye is witnessing a surge in engagement from biotech and pharma companies, leading to a doubling of clinical trial volumes over the last three years.
Please follow the link to learn more.
Pragmatic Clinical Trials in 2024
Pragmatic clinical trials (PCTs) stand as a transformative approach in the biotech and pharmaceutical industries, providing crucial real-world insights into treatment effectiveness within the contexts where they are expected to be applied. Unlike explanatory trials that focus on controlled and specific biological outcomes, PCTs delve into the applicability and generalizability of interventions across diverse clinical settings.
Please follow the link to learn more.
Alzheimer’s Disease Transmission Confirmed in Living Individuals
A groundbreaking study has unveiled compelling evidence of Alzheimer’s disease transmission among living individuals. The research marks a significant breakthrough, demonstrating a case where the amyloid-beta protein, linked to Alzheimer’s pathology, was seemingly transmitted through medical procedures.
Please follow the link to learn more.
Muscle abnormalities worsen after post-exertional malaise in long COVID
In long COVID patients, post-exertional malaise exacerbates fatigue and pain symptoms, but its underlying causes are unclear. Through a longitudinal case-control study, was revealed that skeletal muscle abnormalities worsen after post-exertional malaise induction. These findings shed light on the pathophysiology of post-exertional malaise in long COVID and may aid in understanding similar conditions in post-infectious diseases.
Please follow the link to learn more.
Emerging Pain Relief Drugs: Exploring Vertex’s VX-548
Extensive efforts are underway to create pain-relieving drugs devoid of the drawbacks associated with NSAIDs and opioids. Numerous candidates are undergoing development, though many will not meet expectations. In this series, we’ll delve into the progress of these medications and their potential benefits. Kicking off the discussion is VX-458, a Phase III contender by Vertex.
Please follow the link to learn more.
Role of Phosphorylated α-Synuclein in Healthy Brain Function Discovered
Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, is also involved in the normal processes of how neurons communicate with each other in a healthy brain.
Please follow the link to learn more.
